In most healing stories, the end of treatment marks the start of relief mixed with concern. Because beyond appearances, certain diseases continue to play in the shadows. This is the case of breast cancer, whose remission can hide invisible threats. Recent research questions the passivity of the post-cancer and draw the contours of a new, discreet but potentially decisive strategy.
The existence of these cells is not a new idea. Indeed, animal research has long shown that some cancers left invisible traces behind. These cellular residues, although discreet, could relaunch the disease at any time. Biologist Lewis Chodosh and his team then proved that they were not inert. On the contrary, they triggered very sophisticated survival mechanisms. By targeting precise metabolic routes, such as autophagy or MTOR signal, researchers have reduced their number in mice. In some cases, they even managed to eliminate them completely.
This concept of minimal residual disease, long relegated to the margin of oncological practices, is today an essential link in the understanding of relapses.
A test that shows that the relapses of breast cancer are not inevitable
The idea of taking action led to the implementation of a clinical trial piloted by the Perelman School of Medicine of the University of Pennsylvania. The study, published in the journal Nature Medicine, was conducted on 51 women who finished their treatment against breast cancer. All of them still had dormant tumor cells detected by bone marrow puncture.
Rather than betting on a pharmaceutical innovation, the researchers have used two drugs already approved by the FDA, but so far used in other therapeutic contexts. One targets the autophagy process, the other acts on the MTOR track, a cellular mechanics involved in dormancy. Three groups were formed, one receiving one of the treatments alone, the third combining both.
The results are striking. After six to twelve months of treatment, the majority of patients had no trace of dormant cells. Over the 42 months of follow -up, only two relapses were identified. In the group receiving the two drugs, no recurrence has been observed. Slate specifies that this rate of survival without relapse reaches up to 100% in certain configurations, which is a first at this stage of the disease.
However, this is only a phase 2, still modest in size. Two other trials are already underway in the United States to check these results on a wider sample. But the momentum is given.
Towards a new way of thinking about the after-cancer
Until now, post-therapeutic monitoring has often been limited to regular examinations and the observation of clinical signs. In the absence of symptoms, no intervention was envisaged. This model is based on an ancient idea that the disease only deserves attention when it manifests itself. The approach initiated by the Angela Demihele team offers a breakdown of paradigm.
Rather than waiting for recurrence, it would be possible to act at the end of treatment, to verify the presence of dormant residual cells and to eliminate them before they come back to life. This strategy transforms the post-cancer into an active prevention space, and no longer into a simple anxious observation period.
Beyond clinical profit, the mental load linked to the fear of relapse could also decrease. In the daily life of patients, this latent threat poisons psychological reconstruction. Knowing that tools exist to reduce this risk, even in silence, could reconcile science and experience. And in this new alliance, perhaps the future of a medicine more attentive to the invisible sequelae that healing leaves healing.
